Literature DB >> 33168613

Comparing the Population Pharmacokinetics of and Acute Kidney Injury Due to Polymyxin B in Chinese Patients with or without Renal Insufficiency.

Peile Wang1,2, Qiwen Zhang1,2, Zhenfeng Zhu1,2, Hui Pei3, Min Feng4, Tongwen Sun5, Jing Yang6,2, Xiaojian Zhang1,2.   

Abstract

Despite excellent bactericidal effect, dosing adjustment of polymyxin B for patients with renal insufficiency and polymyxin B-related nephrotoxicity is still a major concern to clinicians. The aim of this study was to compare the population pharmacokinetics (PK) properties of polymyxin B in Chinese patients with different renal functions and to investigate the relationship between PK parameters and polymyxin B-related acute kidney injury (AKI). A total of 37 patients with normal renal function (creatinine clearance ≥ 80 ml/min) and 33 with renal insufficiency (creatinine clearance < 80 ml/min) were included. In the two-compartment population PK models, the central compartment clearance (CL) (2.19 liters/h versus 1.58 liters/h; P < 0.001) and intercompartmental clearance (Q) (13.83 liters/h versus 10.28 liters/h; P < 0.001) values were significantly different between the two groups. The simulated values for AUC across 24 h at steady state (AUCss,24h) for patients with normal renal function were higher than those for patients with renal insufficiency. However, renal dosing adjustment of polymyxin B seemed not to be necessary. In addition, during the treatment, AKI occurred in 23 (32.86%) patients. The polymyxin B AUCss,24h in patients with AKI was significantly higher than that in patients without AKI (108.66 ± 70.10 mg · h/liter versus 66.18 ± 34.79 mg · h/liter; P = 0.001). Both the receiver operating characteristic (ROC) curve and logistic regression analysis showed that an AUCss,24h of >100 mg · h/liter was a good predictor for the probability of nephrotoxicity.
Copyright © 2021 American Society for Microbiology.

Entities:  

Keywords:  AUC; acute kidney injury; polymyxin B; population pharmacokinetics; renal insufficiency

Mesh:

Substances:

Year:  2021        PMID: 33168613      PMCID: PMC7848972          DOI: 10.1128/AAC.01900-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  35 in total

1.  Clinical outcomes associated with polymyxin B dose in patients with bloodstream infections due to carbapenem-resistant Gram-negative rods.

Authors:  Brian C Nelson; Daniel P Eiras; Angela Gomez-Simmonds; Angela S Loo; Michael J Satlin; Stephen G Jenkins; Susan Whittier; David P Calfee; E Yoko Furuya; Christine J Kubin
Journal:  Antimicrob Agents Chemother       Date:  2015-08-31       Impact factor: 5.191

2.  Population Pharmacokinetics of Polymyxin B in Acutely Ill Adult Patients.

Authors:  Cristina Miglis; Nathaniel J Rhodes; Sean N Avedissian; Christine J Kubin; Michael T Yin; Brian C Nelson; Manjunath P Pai; Marc H Scheetz
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

3.  Evaluation of Dose-Fractionated Polymyxin B on Acute Kidney Injury Using a Translational In Vivo Rat Model.

Authors:  Jiajun Liu; Gwendolyn M Pais; Sean N Avedissian; Annette Gilchrist; Andrew Lee; Nathaniel J Rhodes; Alan R Hauser; Marc H Scheetz
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

4.  Quantification of the pharmacokinetic-toxicodynamic relationship of oral docetaxel co-administered with ritonavir.

Authors:  Huixin Yu; Julie M Janssen; Vincent A de Weger; Bastiaan Nuijen; Rik E Stuurman; Serena Marchetti; Jan H M Schellens; Jos H Beijnen; Thomas P C Dorlo; Alwin D R Huitema
Journal:  Invest New Drugs       Date:  2020-04-19       Impact factor: 3.850

Review 5.  Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?

Authors:  Thien B Tran; Tony Velkov; Roger L Nation; Alan Forrest; Brian T Tsuji; Phillip J Bergen; Jian Li
Journal:  Int J Antimicrob Agents       Date:  2016-10-18       Impact factor: 5.283

6.  Validation of a colistin plasma concentration breakpoint as a predictor of nephrotoxicity in patients treated with colistin methanesulfonate.

Authors:  Juan P Horcajada; Luisa Sorlí; Sonia Luque; Natividad Benito; Concepción Segura; Nuria Campillo; Milagro Montero; Erika Esteve; Beatriz Mirelis; Virginia Pomar; Jordi Cuquet; Carmina Martí; Pau Garro; Santiago Grau
Journal:  Int J Antimicrob Agents       Date:  2016-10-07       Impact factor: 5.283

7.  Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study.

Authors:  Maria Helena Rigatto; Tainá F Behle; Diego R Falci; Thiela Freitas; Natane T Lopes; Mariá Nunes; Leonardo W Costa; Alexandre P Zavascki
Journal:  J Antimicrob Chemother       Date:  2015-01-20       Impact factor: 5.790

8.  International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP).

Authors:  Brian T Tsuji; Jason M Pogue; Alexandre P Zavascki; Mical Paul; George L Daikos; Alan Forrest; Daniele R Giacobbe; Claudio Viscoli; Helen Giamarellou; Ilias Karaiskos; Donald Kaye; Johan W Mouton; Vincent H Tam; Visanu Thamlikitkul; Richard G Wunderink; Jian Li; Roger L Nation; Keith S Kaye
Journal:  Pharmacotherapy       Date:  2019-01       Impact factor: 6.251

9.  Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study.

Authors:  Luisa Sorlí; Sonia Luque; Santiago Grau; Núria Berenguer; Concepción Segura; María Milagro Montero; Francisco Alvarez-Lerma; Hernando Knobel; Natividad Benito; Juan P Horcajada
Journal:  BMC Infect Dis       Date:  2013-08-19       Impact factor: 3.090

10.  Personalizing Polymyxin B Dosing Using an Adaptive Feedback Control Algorithm.

Authors:  Elizabeth A Lakota; Cornelia B Landersdorfer; Roger L Nation; Jian Li; Keith S Kaye; Gauri G Rao; Alan Forrest
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

View more
  10 in total

1.  Population Pharmacokinetics of Colistin Sulfate in Critically Ill Patients: Exposure and Clinical Efficacy.

Authors:  Xu-Ben Yu; Xiao-Shan Zhang; Ye-Xuan Wang; Yu-Zhen Wang; Hong-Min Zhou; Fang-Min Xu; Jun-Hui Yu; Li-Wen Zhang; Ying Dai; Zi-Ye Zhou; Chun-Hong Zhang; Guan-Yang Lin; Jing-Ye Pan
Journal:  Front Pharmacol       Date:  2022-06-16       Impact factor: 5.988

2.  Polymyxin B-Associated Nephrotoxicity and Its Predictors: A Retrospective Study in Carbapenem-Resistant Gram-Negative Bacterial Infections.

Authors:  Xiao-Li Wu; Wen-Ming Long; Qiong Lu; Xin-Qi Teng; Ting-Ting Qi; Qiang Qu; Ge-Fei He; Jian Qu
Journal:  Front Pharmacol       Date:  2022-04-28       Impact factor: 5.988

3.  Assessing the predictive performance of population pharmacokinetic models for intravenous polymyxin B in critically ill patients.

Authors:  Patrick O Hanafin; Roger L Nation; Marc H Scheetz; Alexandre P Zavascki; Ana M Sandri; Andrea L Kwa; Benjamin P Z Cherng; Christine J Kubin; Michael T Yin; Jiping Wang; Jian Li; Keith S Kaye; Gauri G Rao
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-11-23

Review 4.  Population pharmacokinetics of polymyxin B: a systematic review.

Authors:  Na Chen; Jianhao Guo; Jiao Xie; Mi Xu; Xing Hao; Kuifen Ma; Yuefeng Rao
Journal:  Ann Transl Med       Date:  2022-02

5.  Polymyxin B in Patients With Renal Impairment: Is It Necessary to Adjust Dose?

Authors:  Ruifang Nie; Dejun Li; Peng Wang; Genquan Yan; Bing Leng
Journal:  Front Pharmacol       Date:  2022-06-28       Impact factor: 5.988

6.  Does Monitoring Total and Free Polymyxin B1 Plasma Concentrations Predict Polymyxin B-Induced Nephrotoxicity? A Retrospective Study in Critically Ill Patients.

Authors:  Yang Deng; Jun-Yuan Gu; Xin Li; Huan Tong; Si-Wei Guo; Bing Xu; You Li; Bi-Kui Zhang; Ying Li; Hai-Ying Huang; Gui-Ying Xiao
Journal:  Infect Dis Ther       Date:  2022-06-11

7.  An area under the concentration-time curve threshold as a predictor of efficacy and nephrotoxicity for individualizing polymyxin B dosing in patients with carbapenem-resistant gram-negative bacteria.

Authors:  Jing Yang; Shaohua Liu; Jingli Lu; Tongwen Sun; Peile Wang; Xiaojian Zhang
Journal:  Crit Care       Date:  2022-10-18       Impact factor: 19.334

8.  Correlation between the drug concentration of polymyxin B and polymyxin B-associated acute kidney injury in critically ill patients: A prospective study.

Authors:  Ying Xu; Pei Liang; Ning Liu; Danjiang Dong; Qin Gu; Xinying Wang
Journal:  Pharmacol Res Perspect       Date:  2022-10

9.  Optimal Empiric Polymyxin B Treatment of Patients Infected with Gram-Negative Organisms Detected Using a Blood Antimicrobial Surveillance Network in China.

Authors:  Xingbing Wu; Chen Huang; Hui Wang; Jinru Ji; Chaoqun Ying; Yonghong Xiao
Journal:  Drug Des Devel Ther       Date:  2021-06-17       Impact factor: 4.162

10.  Nephrotoxicity and Efficacy Assessment of Polymyxin B Use in Renal Transplant Patients.

Authors:  Yu-Xin Wen; Qiang Qu; Wen-Ming Long; Yue Luo; Hai-Hui Zhuang; Xin-Qi Teng; Jian Qu
Journal:  Infect Drug Resist       Date:  2022-01-26       Impact factor: 4.003

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.